Intractable Parathyromatosis despite extensive surgical interventions: A case report with literature review.

INTRODUCTION AND IMPORTANCE: Parathyromatosis is a very rare condition where persistent hyperparathyroidism occurs after surgical excision of the parathyroid gland. That is explained by many theories mainly a seeding of parathyroid gland tissue post parathyroidectomy. We report a rare case presentation of Parathyromatosis and the clinical course with the consequences of her condition. CASE PRESENTATION: a 38 years old female presented first time in 2003 with a parathyroid cyst that underwent excision which was ruptured accidentally and seeding of content happened. As a consequence, she had multiple presentations of recurrent hyperparathyroidism with different locations in the neck region in which parathyroid tissue was found invading muscle, subcutaneous tissue, and surrounding structure, she was managed surgically eight times during 20 years combined with medical management with intermittent remission. DISCUSSION: Parathyromatosis diagnosis is challenging and requires differentiating it from other gland pathology such as adenoma or carcinoma, management must include meticulous en-block resection to eliminate all parathyroid tissue, recurrence is high which may require multiple surgeries. CONCLUSION: managing such a rare condition is very challenging in diagnosis and management ranging from medical therapy to Surgery which may reach multiple attempts to control the disease, we also refer to the reason possibly due to multiple theories of getting this condition. Such a long-term disease, it needs surveillance follow-up to prevent the complication and recurrence.

Propensity score-matched analysis of the endoscopic bilateral axillo-breast approach (BABA) versus conventional open thyroidectomy in patients with benign or intermediate fine-needle aspiration cytology results, a retrospective study.

BACKGROUND: The purpose of this study was to compare the surgical outcomes of endoscopic bilateral axillo-breast approach (BABA) to conventional open thyroidectomy (COT) in patients who had thyroid nodule(s) with a benign or intermediate fine-needle aspiration cytology (FNAC) results. MATERIALS AND METHODS: All patients with benign or intermediate thyroid nodule(s) who underwent BABA (n = 95) or COT (n = 262) between 2008 and 2015 were reviewed. Then, 1:1 propensity score matching was performed, and 66 matched pairs were obtained. Surgical outcomes were then compared. RESULTS: Before matching, patients in the BABA group were significantly younger (36.5 vs. 50.7 years, p < 0.000), predominantly female (97.9% vs. 69.8%, p < 0.000), had smaller tumours (2.1 vs. 2.8 cm, p = 0.002) and more commonly underwent hemithyroidectomy (88.4% vs. 70.6%, p < 0.000) than those in the COT group. After matching, all clinicopathological characteristics were equivalent. BABA was found to be significantly associated with longer operative time (125.3 vs. 79.8 min, p < 0.000), greater drainage volume (132.9 vs. 59.1 ml, p < 0.000), longer postoperative hospital stay (3.1 vs. 2.2 days, p < 0.000), and higher average total medical expense (4000 vs. 3200 US$). However, the incidence of complications did not differ between the groups. CONCLUSION: BABA is comparable to COT in terms of complications and is safe and feasible when performed by experienced surgeons and for carefully selected patients who are concerned about neck scarring. However, the operative time and postoperative hospital stay are significantly longer, which may increase medical expenses.

Goserelin plus tamoxifen compared to chemotherapy followed by tamoxifen in premenopausal patients with early stage-, lymph node-negative breast cancer of luminal A subtype.

OBJECTIVES: To study the outcomes of adjuvant goserelin combined with tamoxifen (GosTam) compared to chemotherapy followed by tamoxifen (ChemTam) in premenopausal patients with early stage, luminal A breast cancer. METHODS: From 2008 until 2013, data were retrospectively collected for premenopausal patients who underwent surgery for invasive tumors that were ≤2.0 cm, node-negative, strongly positive for estrogen and progesterone receptors, HER-2-negative, and Ki-67 < 25%. The patients were divided into two groups according to adjuvant regimen, either GosTam or ChemTam. All patients who underwent different adjuvant regimens were excluded. RESULTS: In total, 235 patients underwent GosTam and 171 patients underwent ChemTam. There were significantly more patients younger than 40 years in the GosTam group (32% GosTam vs. 22% ChemTam, p = 0.031). Mean tumor size was significantly smaller (1.19 cm vs. 1.48 cm, p < 0.001), Ki-67 significantly lower (p = 0.049), and nuclear grade was low in a significant number of patients in the GosTam group (2% vs. 13%, p < 0.001). After a median follow-up of 51.3 months, there was no mortality in either group. There was no significant difference in 5-year disease-free survival (DFS) between the two groups even after univariate analysis considering age, tumor size, nuclear grade, and P53% (GosTam = 98.9% vs. ChemTam = 95.7%, HR = 0.404, 95% CI = [0.073, 2.222], p = 0.248). CONCLUSION: There was no difference between treatment groups, and neither chemotherapy nor ovarian suppression seemed to improve the outcome. Thus, tamoxifen alone might be a sufficient option for this low-risk patient population.